Mehta Pallavi R, Upadhye Dipti S, Sawant Pratibha M, Gorivale Manju S, Nadkarni Anita H, Shanmukhaiah Chandrakala, Ghosh Kanjaksha, Colah Roshan B
National Institute of Immunohaematology, 13th Floor, New MS Building, KEM Hospital Campus, Parel, Mumbai, 400012, India.
Hematology Department, KEM Hospital, Parel, Mumbai, 400012, India.
Ann Hematol. 2015 Dec;94(12):1953-8. doi: 10.1007/s00277-015-2479-8. Epub 2015 Aug 29.
Co-inheritance of triplicated α-genes can alter the clinical and hematological phenotypes of β-thalassemias. We evaluated the phenotypic diversity and transfusion requirements in β-thalassemia heterozygotes, homozygotes, and normal individuals with associated α-gene triplication. Clinical and hematological evaluation was done and the β-thalassemia mutations characterized by a covalent reverse dot blot hybridization/amplification refractory mutation system. Alpha-globin gene triplication was assessed by multiplex PCR. During the last 2.5 years, 181 β-thalassemia patients and β-thalassemia carriers with an unusual clinical presentation were referred to us for screening for the presence of associated α-globin gene triplication. Twenty-nine of them had associated α-gene triplication (3 β-thalassemia homozygotes or compound heterozygotes and 26 β-thalassemia heterozygotes). One β-thalassemia compound heterozygote [IVS 1-5 (G → C) + CD 41/42 (-CTTT)] was anemic at birth and required blood transfusions unusually early by 6 weeks of age. The second patient (4.5 years) was also clinically severe and became transfusion dependent in spite of having one mild β-thalassemia mutation [Capsite +1 (A → C)]. The third case (3.5 years) who was homozygous for a mild β-gene mutation [-88 (C → T)] with α gene triplication was untransfused. The 26 β-thalassemia heterozygotes with associated triplicated α-genes presented variably, with a β-thalassemia intermedia-like presentation. While screening the family members of all these cases, we found another 10 β-thalassemia heterozygotes and 9 normal individuals with α-globin gene triplication; however, all of them were asymptomatic. Beta-thalassemia carriers, homozygotes, and compound heterozygotes with an unusual presentation should be screened for the possible presence of associated α-globin gene triplication which could influence the clinical and hematological presentation.
α基因三倍体的共同遗传可改变β地中海贫血的临床和血液学表型。我们评估了伴有α基因三倍体的β地中海贫血杂合子、纯合子及正常个体的表型多样性和输血需求。进行了临床和血液学评估,并通过共价反向斑点杂交/扩增难治性突变系统对β地中海贫血突变进行了鉴定。通过多重PCR评估α珠蛋白基因三倍体。在过去2.5年中,181例临床表现异常的β地中海贫血患者和β地中海贫血携带者被转诊至我们处,以筛查是否存在相关的α珠蛋白基因三倍体。其中29例伴有α基因三倍体(3例β地中海贫血纯合子或复合杂合子以及26例β地中海贫血杂合子)。1例β地中海贫血复合杂合子[IVS 1-5(G→C)+CD 41/42(-CTTT)]出生时即贫血,在6周龄时异常早地就需要输血。第二例患者(4.5岁)临床症状也很严重,尽管有一个轻度的β地中海贫血突变[帽位点+1(A→C)],仍变得依赖输血。第三例患者(3.5岁)为轻度β基因突变[-88(C→T)]纯合子且伴有α基因三倍体,未接受输血。26例伴有α基因三倍体的β地中海贫血杂合子表现各异,呈中间型β地中海贫血样表现。在对所有这些病例的家庭成员进行筛查时,我们又发现了10例伴有α珠蛋白基因三倍体的β地中海贫血杂合子和9例正常个体;然而,他们均无症状。对于表现异常的β地中海贫血携带者、纯合子和复合杂合子,应筛查是否可能存在相关的α珠蛋白基因三倍体,其可能会影响临床和血液学表现。